Lefford MJ. Transfer of adoptive immunity to tuberculosis in mice. Infect Immunity 1975; 11: 1174–1181.
Orme IM, Collins FM. Protection against Mycobacterium tuberculosis infection by adoptive immunotherapy. Requirement for T cell-deficient recipients. J Exp Med 1983; 158: 74–83.
Cooper AM. Cell-mediated immune responses in tuberculosis. Annu Rev Immunol 2009; 27: 393–422.
Orme IM. The kinetics of emergence and loss of mediator T lymphocytes acquired in response to infection with Mycobacterium tuberculosis. J Immunol 1987; 138: 293–298.
Mogues T, Goodrich ME, Ryan L, LaCourse R, North RJ. The relative importance of T cell subsets in immunity and immunopathology of airborne Mycobacterium tuberculosis infection in mice. J Exp Med 2001; 193: 271–280.
Yao S, Huang D, Chen CY, Halliday L, Wang RC, Chen ZW. CD4+ T cells contain early extrapulmonary tuberculosis (TB) dissemination and rapid TB progression and sustain multieffector functions of CD8+ T and CD3- lymphocytes: mechanisms of CD4+ T cell immunity. J Immunol 2014; 192: 2120–2132.
Havlir DV, Barnes PF. Tuberculosis in patients with human immunodeficiency virus infection. N Engl J Med 1999; 340: 367–373.
Getahun H, Matteelli A, Chaisson RE, Raviglione M. Latent Mycobacterium tuberculosis infection. N Engl J Med 2015; 372: 2127–2135.
Cooper AM, Dalton DK, Stewart TA, Griffin JP, Russell DG, Orme IM. Disseminated tuberculosis in interferon gamma gene-disrupted mice. J Exp Med 1993; 178: 2243–2247.
Cooper AM, Magram J, Ferrante J, Orme IM. Interleukin 12 (IL-12) is crucial to the development of protective immunity in mice intravenously infected with mycobacterium tuberculosis. J Exp Med 1997; 186: 39–45.
Flynn JL, Chan J, Triebold KJ, Dalton DK, Stewart TA, Bloom BR. An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. J Exp Med 1993; 178: 2249–2254.
MacMicking JD, North RJ, LaCourse R, Mudgett JS, Shah SK, Nathan CF. Identification of nitric oxide synthase as a protective locus against tuberculosis. Proc Natl Acad Sci USA 1997; 94: 5243–5248.
Cooper AM, Segal BH, Frank AA, Holland SM, Orme IM. Transient loss of resistance to pulmonary tuberculosis in p47(phox−/−) mice. Infect Immunity 2000; 68: 1231–1234.
Scanga CA, Mohan VP, Tanaka K, Alland D, Flynn JL, Chan J. The inducible nitric oxide synthase locus confers protection against aerogenic challenge of both clinical and laboratory strains of Mycobacterium tuberculosis in mice. Infect Immunity 2001; 69: 7711–7717.
Lyadova IV, Panteleev AV. Th1 and Th17 cells in tuberculosis: protection, pathology, and biomarkers. Mediat Inflamm 2015; 2015: 854507.
Du G, Chen CY, Shen Y, Qiu L, Huang D, Wang R et al. TCR repertoire, clonal dominance, and pulmonary trafficking of mycobacterium-specific CD4+ and CD8+ T effector cells in immunity against tuberculosis. J Immunol 2010; 185: 3940–3947.
Newport MJ, Huxley CM, Huston S, Hawrylowicz CM, Oostra BA, Williamson R et al. A mutation in the interferon-gamma-receptor gene and susceptibility to mycobacterial infection. N Engl J Med 1996; 335: 1941–1949.
Elloumi-Zghal H, Barbouche MR, Chemli J, Bejaoui M, Harbi A, Snoussi N et al. Clinical and genetic heterogeneity of inherited autosomal recessive susceptibility to disseminated Mycobacterium bovis bacille calmette-guerin infection. J Infect Dis 2002; 185: 1468–1475.
Sakai T, Matsuoka M, Aoki M, Nosaka K, Mitsuya H. Missense mutation of the interleukin-12 receptor beta1 chain-encoding gene is associated with impaired immunity against Mycobacterium avium complex infection. Blood 2001; 97: 2688–2694.
Sahiratmadja E, Alisjahbana B, Buccheri S, Di Liberto D, de Boer T, Adnan I et al. Plasma granulysin levels and cellular interferon-gamma production correlate with curative host responses in tuberculosis, while plasma interferon-gamma levels correlate with tuberculosis disease activity in adults. Tuberculosis 2007; 87: 312–321.
Nandi B, Behar SM. Regulation of neutrophils by interferon-gamma limits lung inflammation during tuberculosis infection. J Exp Med 2011; 208: 2251–2262.
Andersen P, Woodworth JS. Tuberculosis vaccines—rethinking the current paradigm. Trends Immunol 2014; 35: 387–395.
Tameris MD, Hatherill M, Landry BS, Scriba TJ, Snowden MA, Lockhart S et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet 2013; 381: 1021–1028.
Orme IM, Robinson RT, Cooper AM. The balance between protective and pathogenic immune responses in the TB-infected lung. Nat Immunol 2015; 16: 57–63.
Cooper AM. T cells in mycobacterial infection and disease. Curr Opin Immunol 2009; 21: 378–384.
Reiley WW, Calayag MD, Wittmer ST, Huntington JL, Pearl JE, Fountain JJ et al. ESAT-6-specific CD4 T cell responses to aerosol Mycobacterium tuberculosis infection are initiated in the mediastinal lymph nodes. Proc Natl Acad Sci USA 2008; 105: 10961–10966.
Wolf AJ, Linas B, Trevejo-Nunez GJ, Kincaid E, Tamura T, Takatsu K et al. Mycobacterium tuberculosis infects dendritic cells with high frequency and impairs their function in vivo. J Immunol 2007; 179: 2509–2519.
Poulsen A. Some clinical features of tuberculosis. 1. Incubation period. Acta tuberculosea Scandinavica 1950; 24: 311–346.
Wallgren A. The time-table of tuberculosis. Tubercle 1948; 29: 245–251.
Shafiani S, Tucker-Heard G, Kariyone A, Takatsu K, Urdahl KB. Pathogen-specific regulatory T cells delay the arrival of effector T cells in the lung during early tuberculosis. J Exp Med 2010; 207: 1409–1420.
Tchilian EZ, Ronan EO, de Lara C, Lee LN, Franken KL, Vordermeier MH et al. Simultaneous immunization against tuberculosis. PLoS ONE 2011; 6: e27477.
Beverley PC, Sridhar S, Lalvani A, Tchilian EZ. Harnessing local and systemic immunity for vaccines against tuberculosis. Mucosal immunology 2014; 7: 20–26.
Jung YJ, Ryan L, LaCourse R, North RJ. Properties and protective value of the secondary versus primary T helper type 1 response to airborne Mycobacterium tuberculosis infection in mice. J Exp Med 2005; 201: 1915–1924.
Jeyanathan M, Mu J, McCormick S, Damjanovic D, Small CL, Shaler CR et al. Murine airway luminal antituberculosis memory CD8 T cells by mucosal immunization are maintained via antigen-driven in situ proliferation, independent of peripheral T cell recruitment. Am J Respir Crit Care Med 2010; 181: 862–872.
Connor LM, Harvie MC, Rich FJ, Quinn KM, Brinkmann V, Le Gros G et al. A key role for lung-resident memory lymphocytes in protective immune responses after BCG vaccination. Eur J Immunol 2010; 40: 2482–2492.
Perdomo C, Zedler U, Kuhl AA, Lozza L, Saikali P, Sander LE et al. Mucosal BCG Vaccination Induces Protective Lung-Resident Memory T Cell Populations against Tuberculosis. mBio 2016; 7: pii: e01686-16.
Gebhardt T, Wakim LM, Eidsmo L, Reading PC, Heath WR, Carbone FR. Memory T cells in nonlymphoid tissue that provide enhanced local immunity during infection with herpes simplex virus. Nat Immunol 2009; 10: 524–530.
Clark RA. Resident memory T cells in human health and disease. Science translational medicine 2015; 7: 269rv261.
Khader SA, Bell GK, Pearl JE, Fountain JJ, Rangel-Moreno J, Cilley GE et al. IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat Immunol 2007; 8: 369–377.
Berry MP, Graham CM, McNab FW, Xu Z, Bloch SA, Oni T et al. An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 2010; 466: 973–977.
Bloom CI, Graham CM, Berry MP, Rozakeas F, Redford PS, Wang Y et al. Transcriptional blood signatures distinguish pulmonary tuberculosis, pulmonary sarcoidosis, pneumonias and lung cancers. PLoS ONE 2013; 8: e70630.
Elnaggar MM, Abdellrazeq GS, Elsisy A, Mahmoud AH, Shyboub A, Sester M et al. Evaluation of antigen specific interleukin-1beta as a biomarker to detect cattle infected with Mycobacterium bovis. Tuberculosis 2017; 105: 53–59.
Kathamuthu GR, Moideen K, Bhaskaran D, Sekar G, Sridhar R, Vidyajayanthi B et al. Reduced systemic and mycobacterial antigen-stimulated concentrations of IL-1beta and IL-18 in tuberculous lymphadenitis. Cytokine 2017; 90: 66–72.
Wang Y, Hu C, Wang Z, Kong H, Xie W, Wang H. Serum IL-1beta and IL-18 correlate with ESR and CRP in multidrug-resistant tuberculosis patients. J Med Res 2015; 29: 426–428.
Mayer-Barber KD, Andrade BB, Barber DL, Hieny S, Feng CG, Caspar P et al. Innate and adaptive interferons suppress IL-1alpha and IL-1beta production by distinct pulmonary myeloid subsets during Mycobacterium tuberculosis infection. Immunity 2011; 35: 1023–1034.
Mayer-Barber KD, Barber DL, Shenderov K, White SD, Wilson MS, Cheever A et al. Caspase-1 independent IL-1beta production is critical for host resistance to mycobacterium tuberculosis and does not require TLR signaling in vivo. J Immunol 2010; 184: 3326–3330.
Hu S, He W, Du X, Yang J, Wen Q, Zhong XP et al. IL-17 production of neutrophils enhances antibacteria ability but promotes arthritis development during mycobacterium tuberculosis infection. EBioMedicine 2017; 23: 88–99.
Wozniak TM, Saunders BM, Ryan AA, Britton WJ. Mycobacterium bovis BCG-specific Th17 cells confer partial protection against Mycobacterium tuberculosis infection in the absence of gamma interferon. Infect Immunity 2010; 78: 4187–4194.
Ahmed M, Smith DM, Hamouda T, Rangel-Moreno J, Fattom A, Khader SA. A novel nanoemulsion vaccine induces mucosal Interleukin-17 responses and confers protection upon Mycobacterium tuberculosis challenge in mice. Vaccine 2017; 35: 4983–4989.
Pereira VB, da Cunha VP, Preisser TM, Souza BM, Turk MZ, De Castro CP et al. Lactococcus lactis carrying a DNA vaccine coding for the ESAT-6 antigen increases IL-17 cytokine secretion and boosts the BCG vaccine immune response. J Appl Microbiol 2017; 122: 1657–1662.
Heidarnezhad F, Asnaashari A, Rezaee SA, Ghezelsofla R, Ghazvini K, Valizadeh N et al. Evaluation of Interleukin17and Interleukin 23 expression in patients with active and latent tuberculosis infection. Iran J Basic Med Sci 2016; 19: 844–850.
You E, Kim MH, Lee WI, Kang SY. Evaluation of IL-2, IL-10, IL-17 and IP-10 as potent discriminative markers for active tuberculosis among pulmonary tuberculosis suspects. Tuberculosis 2016; 99: 100–108.
Wang M, Xu G, Lu L, Xu K, Chen Y, Pan H et al. Genetic polymorphisms of IL-17A, IL-17F, TLR4 and miR-146a in association with the risk of pulmonary tuberculosis. Sci Rep 2016; 6: 28586.
Xu L, Cui G, Jia H, Zhu Y, Ding Y, Chen J et al. Decreased IL-17 during treatment of sputum smear-positive pulmonary tuberculosis due to increased regulatory T cells and IL-10. J Transl Med 2016; 14: 179.
Zhao J, Wen C, Li M. Association analysis of interleukin-17 gene polymorphisms with the risk susceptibility to tuberculosis. Lung 2016; 194: 459–467.
Gopal R, Monin L, Slight S, Uche U, Blanchard E, Fallert Junecko BA et al. Unexpected role for IL-17 in protective immunity against hypervirulent Mycobacterium tuberculosis HN878 infection. PLoS Pathog 2014; 10: e1004099.
Treerat P, Prince O, Cruz-Lagunas A, Munoz-Torrico M, Salazar-Lezama MA, Selman M et al. Novel role for IL-22 in protection during chronic Mycobacterium tuberculosis HN878 infection. Mucosal Immunol 2017; 10: 1069–1081.
Bai X, Shang S, Henao-Tamayo M, Basaraba RJ, Ovrutsky AR, Matsuda JL et al. Human IL-32 expression protects mice against a hypervirulent strain of Mycobacterium tuberculosis. Proc Natl Acad Sci USA 2015; 112: 5111–5116.
Montoya D, Inkeles MS, Liu PT, Realegeno S, Teles RM, Vaidya P et al. IL-32 is a molecular marker of a host defense network in human tuberculosis. Sci Transl Med 2014; 6: 250ra114.
Lazar-Molnar E, Chen B, Sweeney KA, Wang EJ, Liu W, Lin J et al. Programmed death-1 (PD-1)-deficient mice are extraordinarily sensitive to tuberculosis. Proc Natl Acad Sci USA 2010; 107: 13402–13407.
Barber DL, Mayer-Barber KD, Feng CG, Sharpe AH, Sher A. CD4 T cells promote rather than control tuberculosis in the absence of PD-1-mediated inhibition. J Immunol 2011; 186: 1598–1607.
Fujita K, Terashima T, Mio T. Anti-PD1 antibody treatment and the development of acute pulmonary tuberculosis. J Thorac Oncol 2016; 11: 2238–2240.
Sakai S, Kauffman KD, Sallin MA, Sharpe AH, Young HA, Ganusov VV et al. CD4 T cell-derived ifn-gamma plays a minimal role in control of pulmonary mycobacterium tuberculosis infection and must be actively repressed by PD-1 to prevent lethal disease. PLoS Pathog 2016; 12: e1005667.
Guerra-Laso JM, Raposo-Garcia S, Garcia-Garcia S, Diez-Tascon C, Rivero-Lezcano OM. Microarray analysis of Mycobacterium tuberculosis-infected monocytes reveals IL26 as a new candidate gene for tuberculosis susceptibility. Immunology 2015; 144: 291–301.
Che KF, Tengvall S, Levanen B, Silverpil E, Smith ME, Awad M et al. Interleukin-26 in antibacterial host defense of human lungs. Effects on neutrophil mobilization. Am J Respir Crit Care Med 2014; 190: 1022–1031.
Wareham AS, Tree JA, Marsh PD, Butcher PD, Dennis M, Sharpe SA. Evidence for a role for interleukin-17, Th17 cells and iron homeostasis in protective immunity against tuberculosis in cynomolgus macaques. PLoS One 2014; 9: e88149.
Maeurer MJ, Trinder P, Hommel G, Walter W, Freitag K, Atkins D et al. Interleukin-7 or interleukin-15 enhances survival of Mycobacterium tuberculosis-infected mice. Infect Immunity 2000; 68: 2962–2970.
Singh V, Gowthaman U, Jain S, Parihar P, Banskar S, Gupta P et al. Coadministration of interleukins 7 and 15 with bacille Calmette-Guerin mounts enduring T cell memory response against Mycobacterium tuberculosis. J Infect Dis 2010; 202: 480–489.
Lundtoft C, Afum-Adjei Awuah A, Rimpler J, Harling K, Nausch N, Kohns M et al. Aberrant plasma IL-7 and soluble IL-7 receptor levels indicate impaired T-cell response to IL-7 in human tuberculosis. PLoS Pathog 2017; 13: e1006425.
Rane L, Rahman S, Magalhaes I, Ahmed R, Spangberg M, Kondova I et al. Increased (6 exon) interleukin-7 production after M. tuberculosis infection and soluble interleukin-7 receptor expression in lung tissue. Genes and immunity 2011; 12: 513–522.
Lazarevic V, Yankura DJ, DiVito SJ, Flynn JL. Induction of Mycobacterium tuberculosis-specific primary and secondary T-cell responses in interleukin-15-deficient mice. Infect Immunity 2005; 73: 2910–2922.
Saito K, Yajima T, Kumabe S, Doi T, Yamada H, Sad S et al. Impaired protection against Mycobacterium bovis bacillus Calmette-Guerin infection in IL-15-deficient mice. J Immunol 2006; 176: 2496–2504.
Umemura M, Nishimura H, Hirose K, Matsuguchi T, Yoshikai Y. Overexpression of IL-15 in vivo enhances protection against Mycobacterium bovis bacillus Calmette-Guerin infection via augmentation of NK and T cytotoxic 1 responses. J Immunol 2001; 167: 946–956.
Chandrashekara S, Anupama KR, Sambarey A, Chandra N. High IL-6 and low IL-15 levels mark the presence of TB infection: A preliminary study. Cytokine 2016; 81: 57–62.
Pydi SS, Bandaru AR, Venkatasubramanian S, Jonnalagada S, Valluri VL. Vaccine for tuberculosis: up-regulation of IL-15 by Ag85A and not by ESAT-6. Tuberculosis 2011; 91: 136–139.
Moreira-Teixeira L, Redford PS, Stavropoulos E, Ghilardi N, Maynard CL, Weaver CT et al. T Cell-Derived IL-10 Impairs Host Resistance to Mycobacterium tuberculosis Infection. J Immunol 2017; 199: 613–623.
Turner J, Gonzalez-Juarrero M, Ellis DL, Basaraba RJ, Kipnis A, qOrme IM et al. In vivo IL-10 production reactivates chronic pulmonary tuberculosis in C57BL/6 mice. J Immunol 2002; 169: 6343–6351.
Cyktor JC, Carruthers B, Kominsky RA, Beamer GL, Stromberg P, Turner J. IL-10 inhibits mature fibrotic granuloma formation during Mycobacterium tuberculosis infection. J Immunol 2013; 190: 2778–2790.
Beamer GL, Flaherty DK, Assogba BD, Stromberg P, Gonzalez-Juarrero M, de Waal Malefyt R et al. Interleukin-10 promotes Mycobacterium tuberculosis disease progression in CBA/J mice. J Immunol 2008; 181: 5545–5550.
Barnes PF, Lu S, Abrams JS, Wang E, Yamamura M, Modlin RL. Cytokine production at the site of disease in human tuberculosis. Infect Immunity 1993; 61: 3482–3489.
Huard RC, Chitale S, Leung M, Lazzarini LC, Zhu H, Shashkina E et al. The Mycobacterium tuberculosis complex-restricted gene cfp32 encodes an expressed protein that is detectable in tuberculosis patients and is positively correlated with pulmonary interleukin-10. Infect Immunity 2003; 71: 6871–6883.
Almeida AS, Lago PM, Boechat N, Huard RC, Lazzarini LC, Santos AR et al. Tuberculosis is associated with a down-modulatory lung immune response that impairs Th1-type immunity. J Immunol 2009; 183: 718–731.
Bonecini-Almeida MG, Ho JL, Boechat N, Huard RC, Chitale S, Doo H et al. Down-modulation of lung immune responses by interleukin-10 and transforming growth factor beta (TGF-beta) and analysis of TGF-beta receptors I and II in active tuberculosis. Infect Immunity 2004; 72: 2628–2634.
Gopal R, Lin Y, Obermajer N, Slight S, Nuthalapati N, Ahmed M et al. IL-23-dependent IL-17 drives Th1-cell responses following Mycobacterium bovis BCG vaccination. Eur J Immunol 2012; 42: 364–373.
Khader SA, Pearl JE, Sakamoto K, Gilmartin L, Bell GK, Jelley-Gibbs DM et al. IL-23 compensates for the absence of IL-12p70 and is essential for the IL-17 response during tuberculosis but is dispensable for protection and antigen-specific IFN-gamma responses if IL-12p70 is available. J Immunol 2005; 175: 788–795.
Gallegos AM, van Heijst JW, Samstein M, Su X, Pamer EG, Glickman MS. A gamma interferon independent mechanism of CD4 T cell mediated control of M. tuberculosis infection in vivo. PLoS Pathog 2011; 7: e1002052.
Chen X, Zhang M, Liao M, Graner MW, Wu C, Yang Q et al. Reduced Th17 response in patients with tuberculosis correlates with IL-6R expression on CD4+ T Cells. Am J Respir Crit Care Med 2010; 181: 734–742.
Nunes-Alves C, Booty MG, Carpenter SM, Jayaraman P, Rothchild AC, Behar SM. In search of a new paradigm for protective immunity to TB. Nat Reviews Microbiol 2014; 12: 289–299.
Singh A, Mohan A, Dey AB, Mitra DK. Inhibiting the programmed death 1 pathway rescues Mycobacterium tuberculosis-specific interferon gamma-producing T cells from apoptosis in patients with pulmonary tuberculosis. J Infect Dis 2013; 208: 603–615.
Jurado JO, Alvarez IB, Pasquinelli V, Martinez GJ, Quiroga MF, Abbate E et al. Programmed death (PD)-1:PD-ligand 1/PD-ligand 2 pathway inhibits T cell effector functions during human tuberculosis. J Immunol 2008; 181: 116–125.
Gao L, Bai L, Liu J, Lu W, Wang X, Li X et al. Annual risk of tuberculosis infection in rural China: a population-based prospective study. Eur Respir J 2016; 48: 168–178.
De Groote MA, Higgins M, Hraha T, Wall K, Wilson ML, Sterling DG et al. Highly multiplexed proteomic analysis of quantiferon supernatants to identify biomarkers of latent tuberculosis infection. J Clin Microbiol 2017; 55: 391–402.
Sandhu G, Battaglia F, Ely BK, Athanasakis D, Montoya R, Valencia T et al. Discriminating active from latent tuberculosis in patients presenting to community clinics. PLoS ONE 2012; 7: e38080.
Che N, Cheng J, Li H, Zhang Z, Zhang X, Ding Z et al. Decreased serum 5-oxoproline in TB patients is associated with pathological damage of the lung. Clin Chim Acta 2013; 423: 5–9.
Weiner J 3rd, Parida SK, Maertzdorf J, Black GF, Repsilber D, Telaar A et al. Biomarkers of inflammation, immunosuppression and stress with active disease are revealed by metabolomic profiling of tuberculosis patients. PLoS ONE 2012; 7: e40221.
Lai CK, Ho S, Chan CH, Chan J, Choy D, Leung R et al. Cytokine gene expression profile of circulating CD4+ T cells in active pulmonary tuberculosis. Chest 1997; 111: 606–611.
Woodworth JS, Aagaard CS, Hansen PR, Cassidy JP, Agger EM, Andersen P. Protective CD4 T cells targeting cryptic epitopes of Mycobacterium tuberculosis resist infection-driven terminal differentiation. J Immunol 2014; 192: 3247–3258.
Aagaard CS, Hoang TT, Vingsbo-Lundberg C, Dietrich J, Andersen P. Quality and vaccine efficacy of CD4+ T cell responses directed to dominant and subdominant epitopes in ESAT-6 from Mycobacterium tuberculosis. J Immunol 2009; 183: 2659–2668.
Seder RA, Darrah PA, Roederer M. T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol 2008; 8: 247–258.
Harari A, Rozot V, Bellutti Enders F, Perreau M, Stalder JM, Nicod LP et al. Dominant TNF-alpha+ Mycobacterium tuberculosis-specific CD4+ T cell responses discriminate between latent infection and active disease. Nat Med 2011; 17: 372–376.
Jeong YH, Jeon BY, Gu SH, Cho SN, Shin SJ, Chang J et al. Differentiation of antigen-specific T cells with limited functional capacity during Mycobacterium tuberculosis infection. Infect Immunity 2014; 82: 132–139.
Petruccioli E, Petrone L, Vanini V, Sampaolesi A, Gualano G, Girardi E et al. IFNgamma/TNFalpha specific-cells and effector memory phenotype associate with active tuberculosis. J Infect 2013; 66: 475–486.
Day CL, Abrahams DA, Lerumo L, Janse van Rensburg E, Stone L, O'Rie T et al. Functional capacity of Mycobacterium tuberculosis-specific T cell responses in humans is associated with mycobacterial load. J Immunol 2011; 187: 2222–2232.
Qiu Z, Zhang M, Zhu Y, Zheng F, Lu P, Liu H et al. Multifunctional CD4 T cell responses in patients with active tuberculosis. Sci Rep 2012; 2: 216.
Sutherland JS, Adetifa IM, Hill PC, Adegbola RA, Ota MO. Pattern and diversity of cytokine production differentiates between Mycobacterium tuberculosis infection and disease. Eur J Immunol 2009; 39: 723–729.
Caccamo N, Guggino G, Joosten SA, Gelsomino G, Di Carlo P, Titone L et al. Multifunctional CD4(+) T cells correlate with active Mycobacterium tuberculosis infection. Eur J Immunol 2010; 40: 2211–2220.
Han Q, Bagheri N, Bradshaw EM, Hafler DA, Lauffenburger DA, Love JC. Polyfunctional responses by human T cells result from sequential release of cytokines. Proc Natl Acad Sci USA 2012; 109: 1607–1612.
Evans CM, Jenner RG. Transcription factor interplay in T helper cell differentiation. Brief Funct Genomics 2013; 12: 499–511.
Jurado JO, Pasquinelli V, Alvarez IB, Pena D, Rovetta AI, Tateosian NL et al. IL-17 and IFN-gamma expression in lymphocytes from patients with active tuberculosis correlates with the severity of the disease. J Leukoc Biol 2012; 91: 991–1002.
Arlehamn CL, Seumois G, Gerasimova A, Huang C, Fu Z, Yue X et al. Transcriptional profile of tuberculosis antigen-specific T cells reveals novel multifunctional features. J Immunol 2014; 193: 2931–2940.
Lindestam Arlehamn CS, Gerasimova A, Mele F, Henderson R, Swann J, Greenbaum JA et al. Memory T cells in latent Mycobacterium tuberculosis infection are directed against three antigenic islands and largely contained in a CXCR3+CCR6+ Th1 subset. PLoS Pathog 2013; 9: e1003130.
Becattini S, Latorre D, Mele F, Foglierini M, De Gregorio C, Cassotta A et al. T cell immunity. Functional heterogeneity of human memory CD4(+) T cell clones primed by pathogens or vaccines. Science 2015; 347: 400–406.
Lu LL, Chung AW, Rosebrock TR, Ghebremichael M, Yu WH, Grace PS et al. A functional role for antibodies in tuberculosis. Cell 2016; 167: 433–443 e414.
Chambers MA, Gavier-Widen D, Hewinson RG. Antibody bound to the surface antigen MPB83 of Mycobacterium bovis enhances survival against high dose and low dose challenge. FEMS Immunol Med Microbiology 2004; 41: 93–100.
Hamasur B, Haile M, Pawlowski A, Schroder U, Kallenius G, Svenson SB. A mycobacterial lipoarabinomannan specific monoclonal antibody and its F(ab') fragment prolong survival of mice infected with Mycobacterium tuberculosis. Clin Exp Immunol 2004; 138: 30–38.
Lopez Y, Yero D, Falero-Diaz G, Olivares N, Sarmiento ME, Sifontes S et al. Induction of a protective response with an IgA monoclonal antibody against Mycobacterium tuberculosis 16kDa protein in a model of progressive pulmonary infection. Int J Med Microbiol 2009; 299: 447–452.
Williams A, Reljic R, Naylor I, Clark SO, Falero-Diaz G, Singh M et al. Passive protection with immunoglobulin A antibodies against tuberculous early infection of the lungs. Immunology 2004; 111: 328–333.
Roy E, Stavropoulos E, Brennan J, Coade S, Grigorieva E, Walker B et al. Therapeutic efficacy of high-dose intravenous immunoglobulin in Mycobacterium tuberculosis infection in mice. Infect Immunity 2005; 73: 6101–6109.
Guirado E, Amat I, Gil O, Diaz J, Arcos V, Caceres N et al. Passive serum therapy with polyclonal antibodies against Mycobacterium tuberculosis protects against post-chemotherapy relapse of tuberculosis infection in SCID mice. Microbes Infect 2006; 8: 1252–1259.
Olivares N, Leon A, Lopez Y, Puig A, Cadiz A, Falero G et al. The effect of the administration of human gamma globulins in a model of BCG infection in mice. Tuberculosis 2006; 86: 268–272.
Zimmermann N, Thormann V, Hu B, Kohler AB, Imai-Matsushima A, Locht C et al. Human isotype-dependent inhibitory antibody responses against Mycobacterium tuberculosis. EMBO Mol Med 2016; 8: 1325–1339.
Li H, Wang XX, Wang B, Fu L, Liu G, Lu Y et al. Latently and uninfected healthcare workers exposed to TB make protective antibodies against Mycobacterium tuberculosis. Proc Natl Acad Sci USA 2017; 114: 5023–5028.